NCT00332241View on ClinicalTrials.gov

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Autistic Disorder
Interventions
DRUG

Aripiprazole

Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks

DRUG

Placebo

Tablets, Oral, once daily, 8 weeks

Trial Locations (9)

11794

Suny - Stony Brook School Of Medicine, Stony Brook

27599

Univ Of Nc, Chapel Hill

30342

Child Neurology Associates, Pc, Atlanta

33432

Marsella, Gregory, Boca Raton

38105

Ut Medical Group, Memphis

40202

University Of Louisville, Louisville

48302

Neurobehavioral Medicine Group, Bloomfield Hills

77090

Red Oak Psychiatry Associates, Pa, Houston

89128

Center For Psychiatry And Behavioral Medicine, Las Vegas

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00332241 - Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) | Biotech Hunter | Biotech Hunter